American Fusion Inc. (OTC: AMFN) announced an update following the presentation of its Texatron Fusion Engine platform at the IEEE International Conference on Plasma Science (ICOPS) 2026 on June 22. The company’s Chief Technology Officer, Dr. John Brandenburg, presented the technology, and management reported strong engagement from researchers and industry professionals. Extensive follow-up discussions centered on the compact fusion technology and its potential role in future energy production.
The company is advancing discussions with Texas Tech University, Dr. Robert Duncan, and Blankslate Innovation regarding the potential use of a specialized testing facility in Lubbock, Texas. Management believes this facility could accelerate validation efforts and expand scientific capabilities. Additionally, American Fusion recently transported its 5MW pre-production Texatron Fusion Engine to the Fort Worth area for installation and commissioning.
American Fusion is also evaluating the deployment of advanced FT-ICR mass spectrometry technology to enhance plasma diagnostics, isotopic analysis, and system performance validation as it moves toward technical and commercial milestones. The company’s development strategy emphasizes system-level engineering, disciplined intellectual property protection, and scalable architectures intended to support long-term commercial operation.
The Texatron Fusion Engine, a neutronic fusion platform, is designed for modular, infrastructure-grade deployment across industrial, commercial, and grid-constrained applications. The company’s focus on capital discipline and transparent corporate governance underlies its approach to bringing fusion energy to market.
For more details, the full press release is available at https://nnw.fm/j2UVP. Additional news and updates on AMFN can be found in the company’s newsroom at http://nnw.fm/AMFN.
This development matters because it signals progress in compact fusion technology, which could provide a scalable, clean energy source for industrial and grid applications. The engagement at ICOPS and ongoing collaborations with academic institutions underscore the potential for near-term validation and commercialization.
